-
Digital G7 reaches limited deal on child protection, AI energy impact
-
Lula blasts US for labelling Brazil crime factions as terrorists
-
Sooryavanshi's 96 in vain as Gujarat down Rajasthan to reach final
-
Colombian army looks to outsmart guerrillas with drone warfare
-
Trump says making final decision on Iran deal
-
'Age doesn't matter' says veteran Curacao boss Advocaat
-
Unrest outside US immigration detention center, 9 arrested
-
Chancellor swap? Rumours swirl about German leader Merz's future
-
Arteta urges Arsenal to 'own' Champions League final
-
British naked chalk giant gets spruced up
-
Trump mocks Jill Biden over debate 'stroke' claim
-
French Open to fine Vallejo for criticising woman umpire
-
Deschamps guards against World Cup over-confidence
-
Trump says now making 'final determination' on Iran deal
-
Poison? More artists flee Trump's US anniversary concerts
-
Vingegaard nears Giro triumph as teammate Kuss takes stage 19
-
Oil falls, stocks mixed on US-Iran truce prospects
-
Trump says making final decision on proposed Iran deal
-
PSG, Arsenal final has no favourite: Luis Enrique
-
PSG more 'hungry' for Champions League after first taste of glory
-
'I'm afraid for my life': Romanians in shock after drone crash
-
PSG still 'hungry' for Champions League glory: Dembele
-
Iran says no trust in US 'words', waiting for Washington to act
-
Swiatek advances at French Open as Djokovic faces Fonseca
-
Photo and video journalists in Gaza to receive 'Golden Pen' award
-
Trees taking drastic measures to survive climate-driven heat
-
Andreeva sweeps into last 16 at French Open
-
McCullum urges England to 'box smart' like New Zealand
-
Oil falls further, stocks mixed on US-Iran truce prospects
-
France rugby star Drean to have heart surgery
-
Narvaez drops out of Giro d'Italia, points jersey bid over
-
Anti-Israel tennis ball protest disrupts Ireland-Qatar football tie
-
Swiatek qualifies for French Open last 16
-
Vance says progress made as US-Iran deal awaits Trump green light
-
France defender Konate set to leave Liverpool: reports
-
German ex-minister faces perjury charges over failed car toll plan
-
Kanye West cleared to play in Netherlands
-
Loyalty could be fatal to Argentina's World Cup title defence, says Bertoni
-
Stocks rise, oil eases on hopes of US-Iran truce deal
-
Polka-dots and hypnotic riffs fuel viral duo Angine de Poitrine
-
NATO, EU outrage as drone hits Romania apartment block
-
French GDP slips 0.1% in first quarter, raising spectre of recession
-
WHO chief in capital of Ebola-hit DR Congo
-
Azmoun: Iran's absent talisman unafraid of controversy
-
PNG leader says no foreign bases as Australia's defence presence grows
-
Russian drone hits Romania apartment block, drawing NATO, EU outrage
-
Migrants try to flee to Bangladesh fearing India crackdown
-
Digital G7 discusses online child protection
-
'If Ebola comes, we'll be wiped out': DR Congo conflict-displaced
-
'Biggest circus in town' the World Cup set for betting frenzy
Canada health authority approves Pfizer's anti-Covid pill
Canada's health authority said Monday it has approved Pfizer's anti-Covid pill, Paxlovid, for adults at high risk of progressing to serious disease.
The oral treatment was approved after an "expedited review," Health Canada said in a statement on its website, adding that it would continue to monitor its safety and effectiveness.
"No drug, including PAXLOVID TM, is a substitute for vaccination," the statement added.
The drug, which comprises two types of tablet, is the first Covid-19 therapy which can be taken at home, and is potentially a huge step towards ending the pandemic.
"Today's announcement is particularly important as access to easy-to-use treatments could help to reduce the severity of Covid-19 in adults who become newly infected and are at high-risk of progressing to serious illness," said Theresa Tam, Canada's chief public health officer.
The approval comes as Canada, like many countries, has been struggling to contain the Omicron variant of Covid-19.
The French-speaking province of Quebec recently announced it would levy a tax on the unvaccinated, arguing they impose a burden on everyone else.
Paxlovid has so far been authorized in a handful of countries including the United States and Israel, while the European Union has allowed member states to use it ahead of formal approval as an emergency measure against Omicron.
Unlike vaccines, it does not target the ever-evolving spike protein which the coronavirus uses to invade cells.
It should therefore in theory be more variant-proof, and the company has said preliminary lab studies have backed up that hypothesis.
A.Gasser--BTB